Delayed versus immediate exercises following surgery for breast cancer : a systematic reviewSHAMLEY, Delva R; BARKER, Karen; SIMONITE, Vanessa et al.Breast cancer research and treatment. 2005, Vol 90, Num 3, pp 263-271, issn 0167-6806, 9 p.Article

First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinomaMELICHAR, B; KORALEWSKI, P; NEGRIER, S et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1470-1476, issn 0923-7534, 7 p.Article

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patientsVIENS, P; PETIT, T; CVITKOVIC, E et al.Annals of oncology. 2006, Vol 17, Num 3, pp 429-436, issn 0923-7534, 8 p.Article

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer : A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosageGAMELIN, E; BOISDRON-CELLE, M; GUERIN-MEYER, V et al.Journal of clinical oncology. 1999, Vol 17, Num 4, pp 1105-1110, issn 0732-183XArticle

Les marqueurs tumoraux : intérêt clinique = Tumor markers: clinical usefulnessLORTHOLARY, A; DELVA, R; CELLIER, P et al.La Semaine des hôpitaux de Paris. 1992, Vol 68, Num 42, pp 1466-1471, issn 0037-1777Article

Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l'Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL) = Cardiac toxicity of trastuzumab in adjuvant and neoadjuvant breast cancer analysis. Phase IV pharmacovigilance study led by the Observatoire des Médicaments et Innovations Thérapeutiques (OMIT B PL)GRUDE, F; CAMPONE, M; HARDY-BESSARD, A.-C et al.Oncologie (Paris). 2010, Vol 12, Num 5-6, pp 362-368, issn 1292-3818, 7 p.Article

Localisations péritonéales isolées d'un carcinome lobulaire infiltrant du sein : Place de la cœlioscopie = Unique peritoneal localizations of infiltrating lobular cancer of the breast. Contribution of the laparoscopyFONDRINIER, E; GUERIN, O; DELVA, R et al.Journal de gynécologie obstétrique et biologie de la reproduction. 1998, Vol 27, Num 1, pp 87-89, issn 0368-2315Article

Host renal cell carcinoma in kidney transplanted patient : ultrasonography screening studyCOGNY-VAN WEYDEVELT, F; CHAUTARD, D; BOURREE, Y et al.Transplantation proceedings. 1995, Vol 27, Num 2, pp 1786-1788, issn 0041-1345Conference Paper

Carcinome de prostate à petites cellules. Rémission complète après chimio-radiothérapie: à propos d'un cas. Commentaire. Réponse = Small cell carcinoma of the prostate. Report of a case of complete remission in response to combined chemotherapy and radiotherapyDEBRAS, B; CHAUTARD, D; DELVA, R et al.Progrès en urologie (Paris). 1994, Vol 4, Num 4, pp 569-572, issn 1166-7087Article

La pression artérielle ambulatoire des sujets normotendus, définition de valeurs de référence en fonction de l'âge par l'appareil SpacelabsPAGNY, J.Y; DELVA, R; AOUIZERATE, M et al.LA PRESSE MEDICALE. 1987, Vol 16, Num 33, pp 1621-1623Article

Carboplatin/cyclophosphamide or carboplatin/ paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers OvariensTREDAN, O; GEAY, J.-F; FREYER, G et al.Annals of oncology. 2007, Vol 18, Num 2, pp 256-262, issn 0923-7534, 7 p.Article

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)CULINE, S; KERBRAT, P; BIRON, P et al.Annals of oncology. 2007, Vol 18, Num 5, pp 917-924, issn 0923-7534, 8 p.Article

Suppression of heparinization of central venous catheters between cycles of chemotherapy : Results of a phase I studyDELVA, R; GAMELIN, E; LORTHOLARY, A et al.Supportive care in cancer. 1998, Vol 6, Num 4, pp 384-388, issn 0941-4355Article

Maintien de l'intensité de dose d'une chimiothérapie associant carboplatine, cyclophosphamide et étoposide chez la femme de plus de 70 ans atteinte d'un cancer de l'ovaire = Presentation of the dose-intensity from an association carboplatin - cyclosphosphamide - etoposid for women older than 70 presenting an ovarian carcinomaDELVA, R; MEGE, M; GAMELIN, E et al.Bulletin du cancer. 1996, Vol 83, Num 1, pp 63-69, issn 0007-4551Article

Long-term pharmacokinetic behavior of platinum after cisplatin administrationGAMELIN, E; ALLAIN, P; MAILLART, P et al.Cancer chemotherapy and pharmacology. 1995, Vol 37, Num 1-2, pp 97-102, issn 0344-5704Article

Sites implantables en cancérologie. La technique per cutanée : résultats d'une série homogène de 141 cas = Implantable sites in cancerology. The percutaneous technique : a homogeneous series of 141 casesMAILLART, P; LORIMIER, G; MEYER, V et al.Journal de chirurgie (Paris. 1908). 1995, Vol 132, Num 12, pp 495-498, issn 0021-7697Article

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II studySELLE, F; WITTNEBEL, S; CATY, A et al.Annals of oncology. 2014, Vol 25, Num 9, pp 1775-1782, issn 0923-7534, 8 p.Article

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trialFIZAZI, K; GRAVIS, G; LAPLANCHE, A et al.Annals of oncology. 2014, Vol 25, Num 5, pp 987-991, issn 0923-7534, 5 p.Article

Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic studyDIERAS, V; LORTHOLARY, A; LAURENCE, V et al.European journal of cancer (1990). 2013, Vol 49, Num 1, pp 25-34, issn 0959-8049, 10 p.Article

Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer : a phase II multicentre studyGONCALVES, A; DELVA, R; FABBRO, M et al.Bone marrow transplantation (Basingstoke). 2006, Vol 37, Num 7, pp 651-659, issn 0268-3369, 9 p.Article

Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trialLOTZ, J.-P; BUI, B; DUCLOS, B et al.Annals of oncology. 2005, Vol 16, Num 3, pp 411-418, issn 0923-7534, 8 p.Article

A phase ii study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinomaBENNOUNA, J; DELVA, R; GOMEZ, F et al.Oncology. 2003, Vol 64, Num 1, pp 25-27, issn 0030-2414, 3 p.Article

rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy : Response and enhancement of further chemosensitivityGRAVIS, G; VIENS, P; DELVA, R et al.Anticancer research. 1998, Vol 18, Num 5B, pp 3699-3704, issn 0250-7005Article

Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patientsGAMELIN, E; LE BOUIL, A; LARRA, F et al.Clinical cancer research. 1997, Vol 3, Num 6, pp 891-899, issn 1078-0432Article

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FUGAMELIN, E. C; DANQUECHIN-DORVAL, E. M; DUMESNIL, Y. F et al.Cancer. 1996, Vol 77, Num 3, pp 441-451, issn 0008-543XArticle